



## Instant Screens versus DetectiMed® Panel

### Stand Alone Instant Screen Device – No Confirmation Testing

### Instant Screen Device with AIT's DetectiMed® Panel Confirmation Testing

### What DetectiMed® means for your practice

Elevated cut-off levels (opiate at 2,000 ng/mL, oxycodone at 100 ng/mL)

Laboratory screening cut-off levels specifically designed for monitoring patient compliance with pain management treatment

DetectiMed confirmation testing provides unambiguous identification of each drug present – ensuring that any decision you make is based on reliable and accurate results

Limited number of drugs

Extended number of drugs

DetectiMed's broad range of drugs provides the physician with a comprehensive snapshot of patient compliance

Decisions based on screening results without confirmation or consultation brings increased risk

“Tried and True” screening and confirmation testing methods provide reliable results backed by the expertise of AIT's Ph.D.-level toxicologists

DetectiMed minimizes your risk and gives you confidence to make difficult clinical decisions

Limited quality control

Extensive quality control and quality assurance

DetectiMed relies on stringent quality guidelines – providing you with the most accurate and reliable results necessary to make clinical decisions and minimize your risk

Limited selectivity – potential for “false positives”

DetectiMed's confirmation testing provides unambiguous identification of individual drugs – no “false positives”

DetectiMed results are based on confirmation testing, protecting you from making decisions based on false results

Designed for broad applications

DetectiMed is designed and validated specifically for the pain management industry

DetectiMed's sensitivity and selectivity was specifically designed and validated to meet the needs of the pain management physician

## Make decisions based on good science.


The following table shows the percentage of samples that screen above a typical laboratory cut-off but below the standard cut-offs adhered to by traditional instant devices. It also demonstrates that a negative result on a point-of-care test is not always proof that the drug was not ingested.

Drug	Typical Instant Device Cut-Off (ng/mL)	Typical Laboratory Screen Cut-Off (ng/mL)	Percentage of Positive Samples Screening Less Than the Instant Device Cut-Off (ng/mL)*
Buprenorphine	10	5	15.6
Amphetamines	<b>1,000</b>	<b>500</b>	<b>52.5</b>
Opiates	300	50	19.4
	<b>2,000</b>	<b>50</b>	<b>51.4</b>
Oxycodone	100	50	2.3
Benzodiazepines	<b>300</b>	<b>75</b>	<b>29.9</b>
Methadone	300	100	18.4
Barbiturates	300	200	7.9
Cocaine	300	150	21.0
Marijuana	50	20	17.0

Based on 70,596 samples that screened positive in the laboratory from January-December 2008.

\* Total cases adjusted to account for laboratory reporting requirements and potential cross reactivity.

### Example: Opiates



For more information about AIT, please contact us.